Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
UC San Diego And J&J Target Chagas Disease
by Michael McCoy
January 18, 2016
| A version of this story appeared in
Volume 94, Issue 3
Researchers at the Skaggs School of Pharmacy & Pharmaceutical Sciences at the University of California, San Diego, will work with Johnson & Johnson’s Janssen R&D unit to identify new treatments for Chagas disease, a parasitic infection that is the leading cause of heart failure in Latin America. Janssen will provide a team led by Skaggs Dean James McKerrow access to its Jump-Starter library of screening compounds. McKerrow will use the school’s new robotic screening facility to test the compounds for their ability to kill the parasite.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter